Skip to main content

Table 1 Patient characteristics

From: The evolution of rectal and urinary toxicity and immune response in prostate cancer patients treated with two three-dimensional conformal radiotherapy techniques

Characteristics WP (n = 116) PO (n = 81)
Age   
Median 73 74
Range 57-100 57-92
Mean ± SD 72.93 ± 8.55 74.88 ± 7.79
TNM Stage   
T0 1 (0.86%) -
T1 6 (5.17%) 22 (27.16%)
T2 34 (29.31%) 30 (37.04%)
T3 62 (53.44%) 15 (18.52%)
T4 4 (3.45%) 1 (1.24%)
Metastases 2 (1.72%) -
Gleason score   
Median 7 5
Range 2-9 3-10
Initial PSA [ng/mL]   
Median 19 10
Range 2-133 1-97
Mean ± SD 31.00 ± 8.67 12.46 ± 2.34
ADT 93 (80.07%) 33 (40.74%)
Previous surgery   
RP 23 (19.83%) 22 (27.16%)
TURP 7 (6.03%) 5 (6.17%)
Therapy duration (m)   
Median 57 54
Range 33-81 22-80
Mean ± SD 57.50 ± 5.56 54.04 ± 7.03
Recurrence Risk*   
Low 1 (0.86%) 19 (23.46%)
Intermediate 20 (17.24%) 38 (46.91%)
High 94 (81.03%) 23 (28.40%)
Prescription dose (Gy)   
≤ 71 60 (51.72%) 6 (7.41%)
72, 73 53 (45.69%) 72 (88.89%)
≥ 74 3 (2.59%) 3 (3.70%)
Disorders   
Without complications 49 (42.24%) 37 (45.86%)
Cystoureteritis 16 (13.79%) 15 (18.52%)
Cystoureteritis + diarrhea 15 (12.93%) 1 (1.23%)
Proctocolitis + diarrhea 28 (24.14%) 14 (17.28%)
Unknown 8 (6.69%) 14 (17.28%)
  1. *Recurrence risk was determined according to Canadian Consensus (Lukka 2002): low risk (T1-2a, Gleason ≤ 6, PSA < 10 ng/mL), intermediate risk (T2b-2c, Gleason = 7, PSA 10-20 ng/mL), high risk (T3-4, Gleason ≥ 8, PSA > 20 ng/mL)